Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алексион Фармасьютикалс, Инк.filedCriticalАлексион Фармасьютикалс, Инк.
Priority claimed from PCT/US2020/018113external-prioritypatent/WO2020168079A1/en
Publication of EA202192249A1publicationCriticalpatent/EA202192249A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Предложены способы клинического лечения генерализованной миастении гравис (gMG) с помощью антитела к C5 или его антигенсвязывающего фрагмента.Methods for the clinical treatment of generalized myasthenia gravis (gMG) using an anti-C5 antibody or an antigen-binding fragment thereof are proposed.
EA202192249A2019-03-072020-02-13
DOSE AND ADMINISTRATION OF C5 ANTIBODIES FOR THE TREATMENT OF MYASTENIA GRAVIS GENERALIZED
EA202192249A1
(en)